Mirum Pharma Files 8-K on Operations & Financial Condition

Ticker: MIRM · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1759425

Complexity: simple

Sentiment: neutral

Topics: financial-condition, operations, regulation-fd

TL;DR

**Mirum Pharma just dropped an 8-K on its financials, so keep an eye out for details.**

AI Summary

Mirum Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition, as well as Regulation FD disclosure. This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. For shareholders, this matters because it offers transparency into Mirum's financial standing, potentially influencing stock valuation and investment decisions.

Why It Matters

This filing provides an update on Mirum Pharmaceuticals' financial health, which is essential for investors to assess the company's performance and make informed decisions about their holdings.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial information, not indicating any immediate high-risk events.

Analyst Insight

Investors should review the full content of the 8-K filing once available to understand the specific details of Mirum Pharmaceuticals' financial condition and operations, as this summary only indicates the topics covered.

Key Players & Entities

FAQ

What is the purpose of Mirum Pharmaceuticals, Inc.'s 8-K filing dated January 8, 2024?

The 8-K filing by Mirum Pharmaceuticals, Inc. on January 8, 2024, is to report on its Results of Operations and Financial Condition and Regulation FD Disclosure, as indicated in the 'ITEM INFORMATION' section of the filing.

What is the trading symbol and the exchange where Mirum Pharmaceuticals, Inc.'s common stock is registered?

Mirum Pharmaceuticals, Inc.'s common stock, with a par value of $0.0001 per share, trades under the symbol 'MIRM' and is registered on the Nasdaq Global Market, as stated under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the business address and phone number of Mirum Pharmaceuticals, Inc.?

The business address for Mirum Pharmaceuticals, Inc. is 950 Tower Lane, Suite 1050, Foster City, California 94404, and its telephone number is (650) 667-4085, according to the 'BUSINESS ADDRESS' section of the filing.

What is Mirum Pharmaceuticals, Inc.'s state of incorporation and IRS Employer Identification Number?

Mirum Pharmaceuticals, Inc. is incorporated in Delaware and its I.R.S. Employer Identification No. is 83-1281555, as detailed in the header information and the 'FORM 8-K' section.

What is the Central Index Key (CIK) for Mirum Pharmaceuticals, Inc.?

The Central Index Key (CIK) for Mirum Pharmaceuticals, Inc. is 0001759425, as found in the 'COMPANY DATA' section of the filing.

Filing Stats: 611 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-01-08 08:30:56

Key Financial Figures

Filing Documents

02

Item 2.02 Results of Operations and Financial Condition. On January 8, 2024, Mirum Pharmaceuticals, Inc. (the "Company") issued a press release announcing, among other things, the Company's preliminary unaudited revenues and net product sales for the fiscal year ended December 31, 2023 and preliminary unaudited net product sales of LIVMARLI (maralixibat) oral solution. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

01

Item 7.01 Regulation FD Disclosure. On January 8, 2024, in connection with its participation in the J.P. Morgan Healthcare Conference, the Company posted a corporate slide presentation in the "Investors" portion of its website at www.mirumpharma.com. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2. The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated January 8, 2024. 99.2 Investor Presentation dated January 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mirum Pharmaceuticals, Inc. Date: January 8, 2024 By: /s/ Christopher Peetz Christopher Peetz President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing